Identification and validation of stemness-based and ferroptosis-related molecular clusters in pancreatic ductal adenocarcinoma
Copyright © 2024. Published by Elsevier Inc..
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with an extremely poor prognosis. Cancer stem cells (CSCs) are considered to be responsible for the poor survival, recurrence and therapy resistance of PDAC. Ferroptosis plays a crucial role in the sustain and survival of CSCs. Here, we employed a rigorous evaluation of multiple datasets to identify a novel stemness-based and ferroptosis-related genes (SFRGs) signature to access the potential prognostic application. This work we retrieved RNA-sequencing and clinical annotation data from the TCGA, ICGC, GTEx and GEO database, and acquired 26 stem cell gene sets and 259 ferroptosis genes from StemChecker database and FerrDb database, respectively. Based on consensus clustering and ssGSEA analysis, we identified two expression patterns of CSCs traits (C1 and C2). Then, WGCNA analysis was implemented to screen out hub module genes correlated with stemness. Furthermore, differential expression analysis, Pearson correlation analysis, and the Least absolute shrinkage and selection operator (LASSO) and Cox regression were performed to identify the SFRGs and to construct model. In addition, the differences in prognosis, tumor microenvironment (TME) components and therapy responses were evaluated between two risk groups. Finally, we verified the most influential marker ARNTL2 experimentally by western blot, qRT-PCR, sphere formation assay, mitoscreen assay, intracellular iron concentration determination and MDA determination assays. In conclusion, we developed a stemness-based and ferroptosis-related prognostic model, which could help predict overall survival for PDAC patients. Targeting ferroptosis may be a promising therapeutic strategy to inhibit PDAC progression by suppressing CSCs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Translational oncology - 41(2024) vom: 15. Feb., Seite 101877 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ruan, Shiye [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ARNTL2 |
|---|
| Anmerkungen: |
Date Revised 05.02.2024 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.tranon.2024.101877 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367525313 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367525313 | ||
| 003 | DE-627 | ||
| 005 | 20240210233151.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240124s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.tranon.2024.101877 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1287.xml |
| 035 | |a (DE-627)NLM367525313 | ||
| 035 | |a (NLM)38262107 | ||
| 035 | |a (PII)S1936-5233(24)00003-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ruan, Shiye |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Identification and validation of stemness-based and ferroptosis-related molecular clusters in pancreatic ductal adenocarcinoma |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 05.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2024. Published by Elsevier Inc. | ||
| 520 | |a Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with an extremely poor prognosis. Cancer stem cells (CSCs) are considered to be responsible for the poor survival, recurrence and therapy resistance of PDAC. Ferroptosis plays a crucial role in the sustain and survival of CSCs. Here, we employed a rigorous evaluation of multiple datasets to identify a novel stemness-based and ferroptosis-related genes (SFRGs) signature to access the potential prognostic application. This work we retrieved RNA-sequencing and clinical annotation data from the TCGA, ICGC, GTEx and GEO database, and acquired 26 stem cell gene sets and 259 ferroptosis genes from StemChecker database and FerrDb database, respectively. Based on consensus clustering and ssGSEA analysis, we identified two expression patterns of CSCs traits (C1 and C2). Then, WGCNA analysis was implemented to screen out hub module genes correlated with stemness. Furthermore, differential expression analysis, Pearson correlation analysis, and the Least absolute shrinkage and selection operator (LASSO) and Cox regression were performed to identify the SFRGs and to construct model. In addition, the differences in prognosis, tumor microenvironment (TME) components and therapy responses were evaluated between two risk groups. Finally, we verified the most influential marker ARNTL2 experimentally by western blot, qRT-PCR, sphere formation assay, mitoscreen assay, intracellular iron concentration determination and MDA determination assays. In conclusion, we developed a stemness-based and ferroptosis-related prognostic model, which could help predict overall survival for PDAC patients. Targeting ferroptosis may be a promising therapeutic strategy to inhibit PDAC progression by suppressing CSCs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ARNTL2 | |
| 650 | 4 | |a CD133 | |
| 650 | 4 | |a Cancer stem cells | |
| 650 | 4 | |a Ferroptosis | |
| 650 | 4 | |a Pancreatic ductal adenocarcinoma | |
| 700 | 1 | |a Wang, Hailiang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Zhongyan |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yubin |e verfasserin |4 aut | |
| 700 | 1 | |a Cui, Jinwei |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Shanzhou |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Chuanzhao |e verfasserin |4 aut | |
| 700 | 1 | |a Hou, Baohua |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Translational oncology |d 2008 |g 41(2024) vom: 15. Feb., Seite 101877 |w (DE-627)NLM180720333 |x 1936-5233 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2024 |g day:15 |g month:02 |g pages:101877 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.tranon.2024.101877 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2024 |b 15 |c 02 |h 101877 | ||